Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Marcum MicroCap Conference 2017
18 slides from Biorestorative Therapies's conference presentation, Jun 15, 2017
Slide 1: Marcum MicroCap Presentation 2017
— PRESENTATION 2017
Slide 2: Forward-looking statements
Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRestorative Therapies, Inc. (the “Company’), that are not current or historical factual statements may constitute “forward looking” information within the meaning of securit
Slide 3: BioRestorative Therapies company overview and core programs
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease and metabolic disorders. ™ DISC/SPINE PROGRAM (brtxDISC™): + FDA Clearance to Commence Phase 2 Clini
Slide 4: Current treatment options for the BRTX-100-addressable population
Current treatment options for the BRTX-100-addressable population ranae from conservative OTC pain medications ic = (NSAIDs, analgesics) y* ca eaceeeeey Sa = G en discector | oral Medication feo ; Ops SSE ‘Treatment |\ ‘acetaminophen combination) \ ic \ [Posterior lumbar fusion (PLF) \ ior lumbar in
Slide 5: Prevalence of the BRTX-100-addressable patient population
Trinity Partners used a mul ronged approach to determine the prevalence of the BRTX-100-addressable patient population US Adult Population a 248 MM ¥ # With Chronic Lower Back Pain — Prevalence | 248008 t # Diagnosed/Treated ---4f 14.9 MM ¥ I # With Disc Degeneration Sa | 11.9 MM ¢ # With Disc Protr
Slide 6: Lower Back Pain is the Most Common, Disabling and Costly Musculoskeletal Problem
ower Back Pain is the Most Common, the Most Disabling, ana the Most Costly Musculoskeletal Problem Treated Spinal Fusion INTRODUCING A NEW STANDARD OF CARE TO TREAT CHRONIC LUMBAR DISC DISEASE
Slide 7: Disc Therapeutic: BRTX-100 lead cell therapy candidate
sc Therapeutic Disc Therapy to Treat Chronic Lumbar Disc Disease (Protruding and Bulging Discs) ™ BRTX-100 - Lead Cell Therapy Candidate “ = eS Product Formulated from Autologous Hypoxic SS | Cultured Mesenchymal Stem Cells (or MSCs Ne if xt —| Collected from the Patient's Bone Marrow and Co- et Adm
Slide 8: Hypoxic Culture Conditions for Mesenchymal Stem Cell Medicine
\ ein Os 2 Hypoxic Culture Conditions — A Solution for Mesenchymal Stem Cell Based Regenerative Medicine Hypoxic Culture Benefits Increased Cell Proliferation Greater Plasticity Increased Paracrine Effect Increased Cell Survival BRTX-100 - A Safer and More Potent Product BRTX-100 Mesoblast Autologou
Slide 9: BRTX-100 treatment process
Collection and Shipment to BRT of Patient’s Bone Marrow and Blood Production of Thawing and EB eed Injection of + Hypoxic BRTX-100 into Culturing of Patient's Disc Mscs o + Biomaterial Carrier Shipment of BRTX-100 to Clinical Site/Physician
Slide 10: Human Clinical Experience
Human Clinical Experience HUMAN CLINICAL EXPERIENCE SAFETY STUDY faba eta. J Trans! Med (2016) 14252 (DOI 10.1186/12967-016-1015-5. Journal of Translational Medicine RES RES Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chroni
Slide 11: Therapy May Have a Significant Impact on the Morphology of the Disc
Therapy May Have a S$: icant Impact on the Morphology of the Disc ™@ 42 yo Male needed epidural steroid 4/2009 injections multiple times annually PRE-TREATMENT for radiculopathy @ Large central, contained, broad based protrusion (L5-S1) ™ 6 Years Conventional treatment + Narcotics + Epidural Steroid
Slide 12: Phase 2 Trial Design
@ Trial Design: A Phase 2 Prospective, Double-Blinded, Placebo Controlled, Randomized Study, n=72 + Evaluate Safety and Efficacy of a Single Dose of BRTX-100 + 15+ Clinical Trial Sites + Primary Efficacy Endpoint — 6 months + Patient Follow Up — 12 months, 24 months @ Primary Endpoint + Improvement
Slide 13: Unique Product Engineered to Address the Challenges of the Targeted Application
@ Unique Product Engineered to Address the Challenges of the Targeted Application * Autologous Hypoxic-Cultured Cell Product + BRTX-100 is Formulated and Co-Administered with Biomaterial Carrier @ Prior Hypoxic-Cultured Cell Therapy Clinical Experience * BioRestorative Therapies Long Term Safety Stu
Slide 14: ThermoStem program
® Srem Cas = Pre-clinical allogeneic cell-based therapy to target obesity, diabetes and metabolic disorders using brown adipose (fat) derived stem cells (BADSC) to generate brown adipose tissue (BAT) = BAT is a specialized adipose tissue found in the human body that plays a key role in the evolution
Slide 15: Glucose and Body Weight
Glucose and Body Weight Blood Glucose Levels Body Weight Body weight (9) po 12345678 9010213 P 2 —©-Control Weeks after transplantation —©-Control e+ BADSC —8-BADSC 3.45 6 7 8 9 10 11 12 13 Weeks after transplantation Mice fed high chow diet throughout experimentand transplanted with brown adipose d
Slide 16: Triglycerides and Cholesterol Levels
Triglycerides (mg/dl) 8 Triglycerides and Cholesterol Levels Triglycerides Level Cholesterol Level Cholesterol (mg/dl) g control ———_,__. —esansc 100 50 ° 1 2 3 4 0 1 2 3 4 Months after transplantation ‘Months after transplantation Mice fed high chow diet throughout experiment and transplanted with
Slide 17: Brown Fat Delivery Device
Brown Fat Delivery Device Encapsulation Device/BADSCs Encapsulation Device containing BADSC that have been differentiated into brown fat. (A) BADSC inside encapsulation device. (B) BASDC prior to loading (C) Encapsulation Device. HE Mito UCP1 Immunohistochemical analysis of a cross section of an enc
Slide 18: BioRestorative Therapies - biorestorative.com
plorestordtive OTCQB: BRTX ¢ biorestorative.com
BioRestorative Therapies — Marcum MicroCap Conference 2017 on 6ix